REG - Alliance Pharma PLC - Full Year Trading Update

Alliance PharmaAnnouncement

18/01/2022 07:05

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220118:nRSR7426Ya&default-theme=true

RNS Number : 7426Y  Alliance Pharma PLC  18 January 2022

 

 For immediate release
                        18 January 2022

 

ALLIANCE PHARMA PLC

("Alliance" or the "Group")

 

Full Year Trading Update

Strong revenue growth continues with profit ahead of expectations

Alliance Pharma plc (AIM: APH), the international healthcare group, announces
its unaudited trading update for the year ended 31 December 2021 ("the Year"),
ahead of the expected announcement of the Group's audited results on 22 March
2022.

The Group delivered strong growth in the Year with see-through revenue(1) of
£169.6m (2020: £137.5m), up 23% on the prior year (up 27% on a constant
currency basis). Excluding the impact of Amberen™, which was acquired in
December 2020, like-for-like see-through revenues grew 12% on a constant
currency basis. Due to an outperformance in Kelo-Cote™, underlying profit
before tax for the Year is expected to be comfortably ahead of market
expectations.

The Consumer Healthcare business continued to perform well, underpinned by
increased eCommerce activity, driving total net revenues for the Year of
£121.8m (2020: £93.0m), an increase of 31% on the prior year (36% adjusted
for currency). Like-for-like(2) consumer revenues rose 14% on a constant
currency basis. Kelo-Cote delivered another excellent performance,
particularly in the APAC region, with net revenues of £48.8m (2020: £34.7m),
up 47% adjusted for currency and up 41% on a reported basis.

In the US, Amberen generated net revenues of $26.5m (£19.2m) in its first
full year under Group ownership, with H2 2021 revenues up 12% on H2 2020
(under previous ownership) at constant currency. Full year revenues grew 3% on
a constant currency basis, with growth expected to accelerate in 2022.
Following a period of investment to expand its local operating capabilities,
the US business now has an enhanced platform from which to generate strong
growth in Amberen and other existing brands, and to scale up further when
suitable acquisitions are identified.

Nizoral™ revenues started to recover in H2 2021 generating sales of £11.8m
in H2 (£9.0m in H1 2021 and £11.2m in H2 2020), as the challenging regional
trading conditions affecting both supply and demand eased. Consequently, net
revenues of £20.6m (2020: £21.0m) for the Year rose 1% on a constant
currency basis (-2% on a reported basis). We expect further improvement in
2022, as the pandemic recedes, and as Alliance takes full control of the
supply chain following the end of the transition period with J&J.

The Prescription Medicines business delivered robust revenues of £47.8m
(2020: £44.5m), up 8% on the prior year, which reflects a partial return to
the delivery of routine treatments and normalisation of daily life compared
with the early stages of the pandemic in 2020.

Free cash flow remained strong at £30.1m (2020: £34.1m) and, as a result,
net debt fell £22.3m to £87.1m at 31 December 2021 (31 December 2020:
£109.4m), reducing Group leverage(3) below 2.0x (31 December 2020: 2.4x)
in-line with previous guidance. In the absence of further acquisitions, Group
leverage is expected to fall below 1.5x in 2022, reflecting the Group's
continuing strong cash generation.

 

Peter Butterfield, Chief Executive Officer of Alliance, commented:

 

"I'm delighted with the organic double-digit revenue growth delivered by the
Group in 2021, despite the challenging operating environment. Our Consumer
Healthcare business continued to perform well, with Kelo-Cote enjoying another
excellent year of growth as we capitalised on the opportunities identified for
the brand.

"As we move into 2022, with Amberen now fully integrated into our enlarged US
operations, we expect to accelerate growth as we realise the benefits of the
additional revenue opportunities that the brand has brought into the Group.

"Our free cash flow has remained robust, enabling us to continue to reduce
both our net debt and our leverage in 2021. This places the Group in a strong
position to participate in complementary acquisitions focused on the consumer
healthcare space."

 

(1) See-through revenue includes sales from Nizoral™ as if they had been
invoiced by Alliance. For statutory accounting purposes the product margin on
revenue is included within Revenue, in line with IFRS 15. Revenue for 2021 on
a statutory reported basis is expected to be £163.2m, an increase of 26% on
the prior year.

(2 )Like-for-like revenues exclude Amberen in 2021 (£19.2m)

(3 )Adjusted net debt / enlarged Group EBITDA, calculated using pro forma
EBITDA on a trailing 12-month basis

 

This announcement contains inside information for the purposes of Article 7 of
the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law
by virtue of the European Union (withdrawal) act 2018 ("MAR"), and is
disclosed in accordance with the Company's obligations under article 17 of
MAR.

 

For further information:

 

 Alliance Pharma plc                                     + 44 (0)1249 466966
 Head of Investor Relations: Cora McCallum               + 44 (0)1249 705168
 ir@allianceph.comwww.alliancepharma.co.uk

 Buchanan                                                + 44 (0)20 7466 5000
 Mark Court / Sophie Wills / Hannah Ratcliff
 alliancepharma@buchanan.uk.com

 Numis Securities Limited                                + 44 (0)20 7260 1000
 Nominated Adviser: Freddie Barnfield / Duncan Monteith
 Corporate Broking: James Black

 

 Investec Bank plc                + 44 (0) 20 7597 5970
 Corporate Finance: Daniel Adams
 Corporate Broking: Patrick Robb

 

About Alliance

Alliance Pharma plc (AIM: APH) is an international healthcare group. Our
purpose is to improve the lives of consumers and patients through making
available a range of clinically valuable healthcare products.

Our core focus is on the marketing of Consumer Healthcare brands, complemented
by a smaller Prescription Medicines business. In total, we hold marketing
rights to around 80 brands, with revenues generated from a mix of direct,
distributor and e-commerce sales.

Headquartered in the UK, the Group employs around 250 people based in
locations across Europe, North America, and the Asia Pacific region. By
outsourcing our manufacturing and logistics operations, we remain asset-light
and focused on maximising the value of our brands.

For more information on Alliance, please visit our website:
www.alliancepharmaceuticals.com (http://www.alliancepharmaceuticals.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFFFELLFIDLIF